SIGNIFICANCE OF REGULAR SOMATOSTATIN ANALOGUES AND INTERFERON-ALPHA APPLICATION IN PATIENTS wITH HIGHLy DIFFERENTIATED NEUROENDOCRINE TUMORS (CLINICAL CASE)

SIGNIFICANCE OF REGULAR SOMATOSTATIN ANALOGUES AND INTERFERON-ALPHA APPLICATION IN PATIENTS wITH HIGHLy DIFFERENTIATED NEUROENDOCRINE TUMORS (CLINICAL CASE)Emelianova G.S., Gorbunova V.A., Orel N.F., Markovich A.A., Kuzminov A.E., Selchuk V.Yu.N.N. Blokhin Russian Cancer Research Center, 115478, Moscow, Russian Federation Presented clinical case demonstrates the importance of regular use of somatostatin analogues and interferon-alpha in patients with well differentiated NETs.

[1]  W. Hiddemann,et al.  Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  K. Detjen,et al.  Interferon-α: Regulatory Effects on Cell Cycle and Angiogenesis , 2004, Neuroendocrinology.

[3]  A. Grossman,et al.  The diagnosis and medical management of advanced neuroendocrine tumors. , 2004, Endocrine reviews.

[4]  U. Mansmann,et al.  Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Ahrén,et al.  Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours , 2003, The British journal of surgery.

[6]  K. Öberg.  Interferon in the Management of Neuroendocrine GEP-Tumors , 2000, Digestion.

[7]  G. Bell,et al.  Molecular biology of somatostatin receptors. , 1995, Endocrine reviews.

[8]  K. Öberg,et al.  Interferon Therapy of Malignant Endocrine Pancreatic Tumors1 , 1994 .

[9]  H. Verspaget,et al.  Natural killer cell activity in patients with neuroendocrine tumours of the gastrointestinal tract; Relation with circulating gastrointestinal hormones , 1991, Neuropeptides.

[10]  K. Funa,et al.  Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon. , 1983, Clinical and Experimental Immunology.